Lipocine announces financial results for the first quarter ended march 31, 2025

Salt lake city , may 8, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended march 31, 2025 and provided a corporate update. neuroactive steroids lipocine has initiated an outpatient phase 3 safety and efficacy study of lpcn 1154, a non-invasive, rapid onset, oral formulation of brexanolone for the treatment of postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking